FDA advisors vote against two drugs for menopausal hot flashes

Your Health Matters

A view shows the U.S. Food and Drug Administration (FDA) logo at its headquarters in Silver SpringWASHINGTON (Reuters) – Advisers to the Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concluding that neither conferred enough benefit to offset their risk. The panel voted 12-2 against a drug made by Depomed Inc, sending the company's shares down 9.8 percent to $5.89 on the Nasdaq. Depomed's shares fell as low as $5.12 immediately after they resumed trading following a halt pending the results of the panel's meeting. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave